Sells implantable glucose monitors for people with diabetes and their healthcare providers.
10-K for FY2025, filed Mar 2, 2026We are a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose…View ↗
We primarily sell directly to our network of distributors and strategic fulfillment partners, who provide the Eversense system to…View ↗
Our net revenues are derived from sales of the Eversense CGM system which includes the Eversense sensor pack containing the sensor…View ↗
Distributors and strategic fulfillment partners buy Eversense systems and components, with sales counted when delivery terms are met; under consignment, sales count when a patient uses the product.
10-K for FY2025, filed Mar 2, 2026We generate product revenue from sales of the Eversense system and related components and supplies to Ascensia, through the…View ↗
Revenue from product sales is recognized at a point in time when the Customers obtain control of our product based upon the delivery terms…View ↗
Under the consignment model, small quantities of inventory are held at healthcare provider locations to ensure availability when a patient…View ↗
$35.3M
10-K for FY2025, filed Mar 2, 2026
$35.3M ↗
Senseonics sells mainly to distributors and strategic fulfillment partners, which provide Eversense to healthcare providers and patients after a prescription and bill insurance payors. It also supplies products on consignment through healthcare professionals.
10-K for FY2025, filed Mar 2, 2026
10-K for FY2025, filed Mar 2, 2026
A significant portion of the Company’s revenue is derived from one customer, Ascensia. For the year ended December 31, 2025 and 2024, sales…View ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
−$32.7MView ↗
8-K, filed Nov 9, 2026
Senseonics is raising its full-year 2026 global net revenue guidance to $68 million to $70 million from $62 million to $66 million…View ↗
8-K, filed Jun 8, 2026
Following the satisfaction or waiver of customary closing conditions, the closing of each of the European Asset Purchases related to the…View ↗
8-K, filed Mar 12, 2026
As described in the Original Form 8-K, the Master Asset Purchase Agreement also contemplated the negotiation and execution of a series of…View ↗
Growing. Revenue grew 2.6x in 4 years, from $13.7M in FY2021 to $35.3M in FY2025, about 27% a year.
Commercial operations
Senseonics has moved from relying on Ascensia for exclusive worldwide distribution and commercial work to taking over U.S. marketing and sales, while Ascensia's European role has become non-exclusive.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 2, 2026We are in the early commercialization stages of the Eversense brand and are focused on driving awareness of our CGM system amongst people…View ↗
Longer-lasting product
The product range has expanded from earlier Eversense systems to a longer-lasting implantable monitor that has moved from development into commercial sale.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 2, 2026We are a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose…View ↗
Competes with Dexcom, Medtronic, Abbott, Roche Diagnostics, and Ascensia
10-K for FY2025, filed Mar 2, 2026The market for CGM systems is developing and competitive, subject to rapid change and significantly affected by new product introductions.…View ↗
Loading...